Camber Pharmaceuticals Launches Generic Toviaz®

Press Release
Article

Camber Pharmaceuticals is excited to introduce Fesoterodine Fumarate Extended-Release Tablets.

Piscataway, NJ, April 17, 2024–Camber Pharmaceuticals is excited to introduce Fesoterodine Fumarate Extended-Release Tablets.

According to the Cleveland Clinic, approximately 33 million Americans struggle with overactive bladders, impacting about 30% of adult males and 40% of adult females nationwide.

Fesoterodine Fumarate ER Tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.

Fesoterodine Fumarate ER Tablets are available in 30 count bottles in 4 mg and 8 mg strengths.

To learn more about Fesoterodine Fumarate Extended- Release Tablets, please visit https://www.camberpharma.com/products/fesoterodine-fumarate-er/

Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dose manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers and improving quality of life through cost-effective medications.

Related Videos
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Video 12 - "Collaborative Care: Key Stakeholders in HE Treatment and Recovery"
Video 11 - "Optimizing Transitions of Care for Hepatic Encephalopathy Patients"
Video 10 - "Valuable Metrics and Improving Adherence in Patients With ASCVD"
Video 9 - "The Role of Pharmacists in Treating Very High-Risk ASCVD"
Video 6 - "evaluating CDK4/6 inhibitor safety profiles"
Video 5 - "CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC"
Video 8 - "Challenges of Concurrent Administration: RSV and Other Vaccines "
© 2024 MJH Life Sciences

All rights reserved.